Healthcare / Drug Manufacturers - Specialty & GenericJakarta
$230.00
-2.00 (-0.86%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-276.3B · quality 46.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.58T
P/E
N/A
•EV/EBITDA
N/A
•ROE
-49.5%
↓Gross Margin
21.1%
↓Debt/Equity
6.31
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+56.8%
FCF CAGR
—
FCF margin
-19.3%
FCF / Net income
1.40x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.76T · net income $-379.67B · FCF $-532.79B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2760.42B | $2760.42B | $1920.81B | $702.07B | $715.43B |
| Net Income | $-379.67B | $-379.67B | $-330.25B | $-85.22B | $275.24B |
| EBITDA | $-115.97B | $-115.97B | $-30.72B | $15.80B | $358.20B |
| EPS | — | — | -38.91 | -34.20 | 110.44 |
| Gross Margin | 21.1% | 21.1% | 27.9% | 42.1% | 35.1% |
| Operating Margin | -6.1% | -6.1% | -1.5% | -1.2% | -4.2% |
| Net Margin | -13.8% | -13.8% | -17.2% | -12.1% | 38.5% |
| Balance Sheet | |||||
| Debt/Equity | 6.31 | 6.31 | 3.72 | 2.77 | 2.06 |
| Current Ratio | 1.24 | 1.24 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-532.79B | $-532.79B | $-276.26B | $-127.64B | $-40.99B |
| Returns | |||||
| ROE | -49.5% | -49.5% | -31.8% | -23.9% | 62.3% |
| Valuation | |||||
| P/E | — | — | — | — | 7.74 |
| EV/EBITDA | — | — | — | 232.66 | 8.11 |
| P/B | 3.37 | 3.37 | 1.78 | 7.79 | 4.82 |
| Growth & Yield | |||||
| Revenue Growth | 43.7% | 43.7% | 173.6% | -1.9% | — |
| EPS Growth | — | — | -13.8% | -131.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-5.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-38.91 → n/d
Residual
-5.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.